Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 356

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis

Open access
Pedersen, Rikke Nørgaard, Esen, Buket Öztürk, Mellemkjær, Lene, Christiansen, Peer, Ejlertsen, Bent, Lash, Timothy Lee, Nørgaard, Mette, Cronin-Fenton, Deirdre·2022·JNCI: Journal of the National Cancer Institute

Abstract

Background: Extended, more effective breast cancer treatments have increased the prevalence of long-term survivors. We investigated the risk of late breast cancer recurrence (BCR), 10 years or more after primary diagnosis, and associations between patient and tumor characteristics at primary diagnosis and late BCR up to 32 years after primary breast cancer diagnosis. Methods: Using the Danish Breast Cancer Group clinical database, we identified all women with an incident early breast cancer diagnosed during 1987-2004. We restricted to women who survived 10 years without a recurrence or second cancer (10-year disease-free survivors) and followed them from 10 years after breast cancer diagnosis date until late recurrence, death, emigration, second cancer, or December 31, 2018. We calculated incidence rates per 1000 person-years and cumulative incidences for late BCR, stratifying by patient and tumor characteristics. Using Cox regression, we calculated adjusted hazard ratios for late BCR accounting for competing risks. Results: Among 36 924 women with breast cancer, 20 315 became 10-year disease-free survivors. Of these, 2595 developed late BCR (incidence rate = 15.53 per 1000 person-years, 95% confidence interval = 14.94 to 16.14; cumulative incidence = 16.6%, 95% confidence interval = 15.8% to 17.5%) from year 10 to 32 after primary diagnosis. Tumor size larger than 20 mm, lymph node–positive disease, and estrogen receptor–positive tumors were associated with increased cumulative incidences and hazards for late BCR. Conclusions: Recurrences continued to occur up to 32 years after primary diagnosis. Women with high lymph node burden, large tumor size, and estrogen receptor–positive tumors had increased risk of late recurrence. Such patients may warrant extended surveillance, more aggressive treatment, or new therapy approaches.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djab202

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Research works printed but not linked: 12

  1. Pachmann, 2011, Tumor cell seeding during surgery—possible contribution to metastasis formations, Cancers (Basel), 3, 2540, 10.3390/cancers3022540 · doi:10.3390/cancers3022540
  2. Mamby, 1993, Metastatic breast cancer 39 years after primary treatment, Wis Med J, 92, 567
  3. Tashima, 2014, A case of local recurrence developing thirty-nine years after mastectomy for breast cancer, Gan To Kagaku Ryoho, 41, 357
  4. Kostev, 2018, 20-year risk of breast cancer recurrence, Breast Cancer Res Treat, 168, 765, 10.1007/s10549-017-4636-3 · doi:10.1007/s10549-017-4636-3
  5. Jensen, 2003, Validity and representativity in the Danish Breast Cancer Cooperative Group--a study on protocol allocation and data validity from one county to a multi-centre database, Acta Oncol Stockh Oncol, 42, 179, 10.1080/02841860310000737 · doi:10.1080/02841860310000737
  6. Pedersen, 2020, Validation of an algorithm to ascertain late breast cancer recurrence using Danish Medical Registries, Clin Epidemiol, 12, 1083, 10.2147/CLEP.S269962 · doi:10.2147/clep.s269962
  7. Christiansen, 2008, Recurrence pattern and prognosis in low-risk breast cancer patients--data from the DBCG 89-A programme, Acta Oncol Stockh Oncol, 47, 691, 10.1080/02841860802056594 · doi:10.1080/02841860802056594
  8. Talman, 2007, Invasive lobular breast cancer. Prognostic significance of histological malignancy grading, Acta Oncol, 46, 803, 10.1080/02841860601137397 · doi:10.1080/02841860601137397
  9. Anderson, 2018, Breast-cancer recurrence after stopping endocrine therapy, N Engl J Med, 378, 870, 10.1056/NEJMc1715968 · doi:10.1056/nejmc1715968
  10. Bodilsen, 2016, Importance of margin width in breast-conserving treatment of early breast cancer, J Surg Oncol, 113, 609, 10.1002/jso.24224 · doi:10.1002/jso.24224
  11. Giannakeas, 2019, A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy, Breast Cancer Res Treat, 177, 691, 10.1007/s10549-019-05334-5 · doi:10.1007/s10549-019-05334-5
  12. Narod, 2020, Late recurrences after estrogen receptor–positive breast cancer, JAMA Oncol, 6, 301, 10.1001/jamaoncol.2019.5579 · doi:10.1001/jamaoncol.2019.5579

Cited by

See all 356

Metadata

Authors
Pedersen, R. N., Esen, B. Ö., Mellemkjær, L., Christiansen, P., Ejlertsen, B., Lash, T. L., Nørgaard, M., & Cronin-Fenton, D.
Venue
JNCI: Journal of the National Cancer Institute
Published
2021-11-08
Volume
114
Issue
3
Pages
391-399
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
OpenAlex
W3211678510
Cited by
356
References
31
FWCI
15.43
Type
journal article
Language
en
Open access
hybrid
Funders
  • DCF from the Danish Cancer Society (“Knæk Cancer” R147-A10100)
  • Aarhus University

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis. https://app.cochat.ai/papers/10.1093/jnci/djab202
The paper
Pedersen, R. N., Esen, B. Ö., Mellemkjær, L., Christiansen, P., Ejlertsen, B., Lash, T. L., Nørgaard, M., & Cronin-Fenton, D. (2022). The Incidence of Breast Cancer Recurrence 10-32 Years After Primary Diagnosis. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djab202

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.